These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14455154)

  • 21. [The importance of tissue culture for hormone therapy in breast carcinoma].
    KELLNER G; TURCIC G
    Klin Med Osterr Z Wiss Prakt Med; 1962 Feb; 17():83-9. PubMed ID: 14454991
    [No Abstract]   [Full Text] [Related]  

  • 22. Urinary estrogen metabolites and breast cancer: a combined analysis of individual level data.
    Dallal CM; Stone RA; Cauley JA; Ness RB; Vogel VG; Fentiman IS; Fowke JH; Krogh V; Loft S; Meilahn EN; Muti P; Olsen A; Overvad K; Sieri S; Tjønneland A; Ursin G; Wellejus A; Taioli E
    Int J Biol Markers; 2013 Apr; 28(1):3-16. PubMed ID: 22865302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of estrogenic hormone on advanced carcinoma of the female breast.
    HERRMANN JB; ADAIR FE; WOODARD HQ
    Arch Surg (1920); 1947 Jan; 54(1):1-9. PubMed ID: 20286074
    [No Abstract]   [Full Text] [Related]  

  • 24. Ovarian ablation as treatment for young women with breast cancer.
    Davidson NE
    J Natl Cancer Inst Monogr; 1994; (16):95-9. PubMed ID: 7528032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
    Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of xenoestrogens and endogenous sources of estrogens on the occurrence of premenopausal breast cancer in Iran.
    Bidgoli SA; Eftekhari T; Sadeghipour R
    Asian Pac J Cancer Prev; 2011; 12(9):2425-30. PubMed ID: 22296395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocrine treatment of breast cancer.
    Ravdin PM
    Curr Ther Endocrinol Metab; 1994; 5():556-62. PubMed ID: 7704791
    [No Abstract]   [Full Text] [Related]  

  • 29. Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women.
    Yoshimoto N; Nishiyama T; Toyama T; Takahashi S; Shiraki N; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
    Cancer Sci; 2011 Nov; 102(11):2065-72. PubMed ID: 21790896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings.
    McDonald Wade S; Hackney MH; Khatcheressian J; Lyckholm LJ
    Oncology; 2008; 75(3-4):192-202. PubMed ID: 18841034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of estrogens and androgens in advanced mammary cancer; clinical and laboratory study of 105 female patients.
    ADAIR FE; MELLORS RC
    J Am Med Assoc; 1949 Aug; 140(15):1193-1200. PubMed ID: 18136181
    [No Abstract]   [Full Text] [Related]  

  • 34. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.
    Flågeng MH; Knappskog S; Gjerde J; Lønning PE; Mellgren G
    PLoS One; 2015; 10(8):e0134351. PubMed ID: 26247365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [On a case of breast cancer: radiation therapy with administration of estrogens].
    VERBEETEN BG
    J Belge Radiol; 1959; 42():316-22. PubMed ID: 13841730
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of premenopausal women with primary breast cancer.
    Woodman CB; Singleton J; Coyne J; Baildam A
    Br J Surg; 1996 Sep; 83(9):1256-7. PubMed ID: 8983621
    [No Abstract]   [Full Text] [Related]  

  • 40. [Aromatase inhibitors in risk reduction of breast cancer: potential use in premenopausal women].
    Kubatka P; Péc M
    Klin Onkol; 2009; 22(6):268-72. PubMed ID: 20099744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.